Lactate Transporter SLC16A3 (MCT4) as an Onco-Immunological Biomarker Associating Tumor Microenvironment and Immune Responses in Lung Cancer

References

• Certo M, Tsai CH, Pucino V, et al. Lactate modulation of immune responses in inflammatory versus tumour microenvironments. Nat Rev Immunol. 2021;21(3):151–161. doi:10.1038/s41577-020-0406-2
   PubMed Web of Science ®Google Scholar
• Wang JX, Choi SYC, Niu X, et al. Lactic acid and an acidic tumor microenvironment suppress anticancer immunity. Int J Mol Sci. 2020;21(21):8363. doi:10.3390/ijms21218363
   PubMed Web of Science ®Google Scholar
• Fischer K, Hoffmann P, Voelkl S, et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood. 2007;109(9):3812–3819. doi:10.1182/blood-2006-07-035972
   PubMed Web of Science ®Google Scholar
• Feng J, Yang H, Zhang Y, et al. Tumor cell-derived lactate induces TAZ-dependent upregulation of PD-L1 through GPR81 in human lung cancer cells. Oncogene. 2017;36(42):5829–5839. doi:10.1038/onc.2017.188
   PubMed Web of Science ®Google Scholar
• Brand A, Singer K, Koehl GE, et al. LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells. Cell Metab. 2016;24(5):657–671. doi:10.1016/j.cmet.2016.08.011
   PubMed Web of Science ®Google Scholar
• Brown TP, Bhattacharjee P, Ramachandran S, et al. The lactate receptor GPR81 promotes breast cancer growth via a paracrine mechanism involving antigen-presenting cells in the tumor microenvironment. Oncogene. 2020;39(16):3292–3304. doi:10.1038/s41388-020-1216-5
   PubMed Web of Science ®Google Scholar
• Ranganathan P, Shanmugam A, Swafford D, et al. GPR81, a cell-surface receptor for lactate, regulates intestinal homeostasis and protects mice from experimental colitis. J Immunol. 2018;200(5):1781–1789. doi:10.4049/jimmunol.1700604
   PubMed Web of Science ®Google Scholar
• Zhang D, Tang Z, Huang H, et al. Metabolic regulation of gene expression by histone lactylation. Nature. 2019;574(7779):575–580. doi:10.1038/s41586-019-1678-1
   PubMed Web of Science ®Google Scholar
• Petty AJ, Li A, Wang X, et al. Hedgehog signaling promotes tumor-associated macrophage polarization to suppress intratumoral CD8+ T cell recruitment. J Clin Invest. 2019;129(12):5151–5162. doi:10.1172/JCI128644
   PubMed Web of Science ®Google Scholar
• Shan T, Chen S, Chen X, et al. M2-TAM subsets altered by lactic acid promote T-cell apoptosis through the PD-L1/PD-1 pathway. Oncol Rep. 2020;44(5):1885–1894. doi:10.3892/or.2020.7767
   PubMed Web of Science ®Google Scholar
• Brown TP, Ganapathy V. Lactate/GPR81 signaling and proton motive force in cancer: role in angiogenesis, immune escape, nutrition, and Warburg phenomenon. Pharmacol Ther. 2020;206:107451. doi:10.1016/j.pharmthera.2019.107451
   PubMed Web of Science ®Google Scholar
• García-Cañaveras JC, Chen L, Rabinowitz JD. The tumor metabolic microenvironment: lessons from lactate. Cancer Res. 2019;79(13):3155–3162. doi:10.1158/0008-5472.CAN-18-3726
   PubMed Web of Science ®Google Scholar
• Payen VL, Mina E, Van Hée VF, et al. Monocarboxylate transporters in cancer. Mol Metab. 2020;33:48–66. doi:10.1016/j.molmet.2019.07.006
   PubMed Web of Science ®Google Scholar
• Contreras-Baeza Y, Sandoval PY, Alarcón R, et al. Monocarboxylate transporter 4 (MCT4) is a high affinity transporter capable of exporting lactate in high-lactate microenvironments. J Biol Chem. 2019;294(52):20135–20147. doi:10.1074/jbc.RA119.009093
   PubMed Web of Science ®Google Scholar
• Marchiq I, Le Floch R, Roux D, et al. Genetic disruption of lactate/H+ symporters (MCTs) and their subunit CD147/BASIGIN sensitizes glycolytic tumor cells to phenformin. Cancer Res. 2015;75(1):171–180. doi:10.1158/0008-5472.CAN-14-2260
   PubMed Web of Science ®Google Scholar
• Kim HK, Lee I, Bang H, et al. MCT4 expression is a potential therapeutic target in colorectal cancer with peritoneal carcinomatosis. Mol Cancer Ther. 2018;17(4):838–848. doi:10.1158/1535-7163.MCT-17-0535
   PubMed Web of Science ®Google Scholar
• Chen HL, OuYang HY, Le Y, et al. Aberrant MCT4 and GLUT1 expression is correlated with early recurrence and poor prognosis of hepatocellular carcinoma after hepatectomy. Cancer Med. 2018;7(11):5339–5350. doi:10.1002/cam4.1521
   PubMed Web of Science ®Google Scholar
• Zhao Z, Han F, He Y, et al. Stromal-epithelial metabolic coupling in gastric cancer: stromal MCT4 and mitochondrial TOMM20 as poor prognostic factors. Eur J Surg Oncol. 2014;40(10):1361–1368. doi:10.1016/j.ejso.2014.04.005
   PubMed Web of Science ®Google Scholar
• Sun Q, Hu LL, Fu Q. MCT4 promotes cell proliferation and invasion of castration-resistant prostate cancer PC-3 cell line. EXCLI J. 2019;18:187–194. doi:10.17179/excli2018-1879
   PubMed Web of Science ®Google Scholar
• Zhao Y, Zhao B, Yan WH, et al. Integrative analysis identified MCT4 as an independent prognostic factor for bladder cancer. Front Oncol. 2021;11:704857. doi:10.3389/fonc.2021.704857
   PubMed Web of Science ®Google Scholar
• Meijer TW, Schuurbiers OC, Kaanders JH, et al. Differences in metabolism between adeno- and squamous cell non-small cell lung carcinomas: spatial distribution and prognostic value of GLUT1 and MCT4. Lung Cancer. 2012;76(3):316–323. doi:10.1016/j.lungcan.2011.11.006
   PubMed Web of Science ®Google Scholar
• Izumi H, Takahashi M, Uramoto H, et al. Monocarboxylate transporters 1 and 4 are involved in the invasion activity of human lung cancer cells. Cancer Sci. 2011;102(5):1007–1013. doi:10.1111/j.1349-7006.2011.01908.x
   PubMed Web of Science ®Google Scholar
• Kuo TC, Huang KY, Yang SC, et al. Monocarboxylate transporter 4 is a therapeutic target in non-small cell lung cancer with aerobic glycolysis preference. Mol Ther Oncolytics. 2020;18:189–201. doi:10.1016/j.omto.2020.06.012
   PubMed Web of Science ®Google Scholar
• Markou A, Tzanikou E, Kallergi G, et al. Evaluation of Monocarboxylate Transporter 4 (MCT4) expression and its prognostic significance in circulating tumor cells from patients with early stage non-small-cell lung cancer. Front Cell Dev Biol. 2021;9:641978. doi:10.3389/fcell.2021.641978
   PubMed Web of Science ®Google Scholar
• Xue L, Liu J, Xie J, Luo J. Prognostic value of SLC16A3(MCT4) in lung adenocarcinoma and its clinical significance. Int J Gen Med. 2021;14:8413–8425. doi:10.2147/IJGM.S337615
   PubMed Web of Science ®Google Scholar
• Yuen KC, Liu LF, Gupta V, et al. High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade. Nat Med. 2020;26(5):693–698. doi:10.1038/s41591-020-0860-1
   PubMed Web of Science ®Google Scholar
• Kim JH. Interleukin-8 in the tumor immune niche: lessons from comparative oncology. Adv Exp Med Biol. 2020;1240:25–33. doi:10.1007/978-3-030-38315-2_2
   PubMed Web of Science ®Google Scholar
• Dong F, Qin X, Wang B, et al. ALKBH5 facilitates hypoxia-induced paraspeckle assembly and IL8 secretion to generate an immunosuppressive tumor microenvironment. Cancer Res. 2021;81(23):5876–5888. doi:10.1158/0008-5472.CAN-21-1456
   PubMed Web of Science ®Google Scholar
• Fousek K, Horn LA, Palena C. Interleukin-8: a chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression. Pharmacol Ther. 2021;219:107692. doi:10.1016/j.pharmthera.2020.107692
   PubMed Web of Science ®Google Scholar
• Sun L, Wang Q, Chen B, et al. Gastric cancer mesenchymal stem cells derived IL-8 induces PD-L1 expression in gastric cancer cells via STAT3/mTOR-c-Myc signal axis. Cell Death Dis. 2018;9(9):928. doi:10.1038/s41419-018-0988-9
   PubMed Web of Science ®Google Scholar